As President and Chief Executive Officer, Michael Egholm, PhD, leads Standard BioTools in its mission to unleash its next-generation technologies to help drive innovation in the life science industry. Under his direction, Standard BioTools is expected to grow into a best-in-class solutions partner to biopharmaceutical researchers through the expansion of in-house technologies and future acquisitions.
Michael brings more than 25 years of proven leadership in developing and commercializing innovative technologies that drive success in the discovery and development of biopharmaceuticals. Prior to joining Standard BioTools, he served as the Chief Technology Officer of Danaher Life Sciences as well as the founder and leader of the Danaher Corporation’s (NYSE:DHR) venture fund. During that time, he led Danaher’s Pall Corporation biopharmaceuticals business, where he played a central role in redesigning its go-to-market structure, leading to the company’s multibillion-dollar revenue today.
Prior to Danaher, Michael was the Chief Technology Officer at Roche’s 454 Life Sciences Corporation, the first company to successfully commercialize next-generation sequencing. There, he spearheaded several large, high-profile programs, including the Neanderthal Sequencing project and the sequencing of the first individual human genome.
An elected member of the Royal Danish Academy of Sciences and Letters, Michael is the named inventor of 40 U.S. patents. While a research associate at the University of Copenhagen, he was lead inventor of peptide nucleic acids (PNA) technology, a synthetic form of DNA, for which he earned his PhD in organic chemistry. More than 2,300 peer-reviewed papers have been published on the properties and uses of PNA, including 42 authored by Michael. He has published more than 100 research papers, with several in the most prestigious peer-reviewed journals, including Science, Nature, and The New England Journal of Medicine.
During his personal time, Michael is an avid runner, yogi, and scuba diver and an instrument-rated private pilot.
What is Michael Egholm's net worth?
The estimated net worth of Michael Egholm is at least $3.97 million as of May 23rd, 2025. Dr. Egholm owns 2,741,191 shares of Standard BioTools stock worth more than $3,974,727 as of December 15th. This net worth estimate does not reflect any other investments that Dr. Egholm may own. Additionally, Dr. Egholm receives a salary of $640,340.00 as President & CEO at Standard BioTools. Learn More about Michael Egholm's net worth.
How old is Michael Egholm?
What is Michael Egholm's salary?
How do I contact Michael Egholm?
Has Michael Egholm been buying or selling shares of Standard BioTools?
Michael Egholm has not been actively trading shares of Standard BioTools during the last quarter. Most recently, Michael Egholm sold 5,473 shares of the business's stock in a transaction on Friday, May 23rd. The shares were sold at an average price of $0.94, for a transaction totalling $5,144.62. Following the completion of the sale, the chief executive officer now directly owns 2,741,191 shares of the company's stock, valued at $2,576,719.54. Learn More on Michael Egholm's trading history.
Who are Standard BioTools' active insiders?
Are insiders buying or selling shares of Standard BioTools?
In the last twelve months, Standard BioTools insiders bought shares 24 times. They purchased a total of 17,279,179 shares worth more than $21,064,912.74. In the last twelve months, insiders at the sold shares 9 times. They sold a total of 58,089 shares worth more than $57,450.84. The most recent insider tranaction occured on December, 4th when Director Casdin Partners Master Fund, L bought 150,000 shares worth more than $217,500.00. Insiders at Standard BioTools own 23.2% of the company.
Learn More about insider trades at Standard BioTools. Information on this page was last updated on 12/4/2025.
